Status:
COMPLETED
Controlled Trial of Valacyclovir in Infectious Mononucleosis
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
Minnesota Medical Foundation
Hoffmann-La Roche
Conditions:
Infectious Mononucleosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe ...
Detailed Description
University of Minnesota students 18 years of age or older who are referred by the Boynton student health service during the first 7 days of infectious mononucleosis are eligible to participate. All of...
Eligibility Criteria
Inclusion
- Clinical diagnosis of infectious mononucleosis with onset no more the 7 days before enrollment; willingness to sign informed consent
- Willingness to provide blood and oral washing samples at regular intervals
- Females must have a negative urine pregnancy test and agree to use effective contraception (barrier or hormonal) for the first 30 days of the study if assigned to valacyclovir
- Corticosteroids are permitted only if prescribed by the subject's primary physisican for treatment of this acute disease
Exclusion
- Previous history of mono
- Pregnant or breast feeding
- End-stage renal or liver disease
- Immunosuppressed due to underlying medical disease and/or immunomodulating medications prior to enrollment
- Onset of present illness \>7 days ago
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00274404
Start Date
February 1 2004
End Date
September 1 2005
Last Update
October 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota Clinical Virology Clinic
Minneapolis, Minnesota, United States, 55455-0392